Top artificial intelligence executives, including Sam Altman of OpenAI, Demis Hassabis of Google DeepMind, and Dario Amodei of Anthropic, have jointly urged the U.S. Congress to enact legislation mandating comprehensive safety screening for all synthetic DNA and RNA orders. The open letter, signed by leaders from Microsoft, Meta, and major biotech firms alongside biosafety experts, warns that rapidly advancing AI models are dramatically lowering the technical barriers to designing biological threats. Historically, acquiring the knowledge required to synthesize pathogens demanded specialized expertise and access to restricted scientific literature. AI systems, however, can aggregate fragmented data across publications, patents, and databases, effectively guiding bad actors to unscreened suppliers and instructing them on how to modify gene sequences to evade existing detection algorithms. Recent research has demonstrated that AI-generated protein designs can successfully bypass commercial screening tools by proposing novel sequences structurally similar to known threats but absent from regulatory blacklists. The call for federal intervention follows a regulatory vacuum. The Trump administration recently rescinded a Biden-era executive order that required federally funded entities to procure synthetic genes only from vetted suppliers. While the White House has pledged new screening guidelines, industry advocates argue that only binding congressional legislation can enforce uniform compliance across all commercial vendors, regardless of funding status. A bipartisan bill addressing the issue has been introduced but lacks sufficient momentum. Proponents emphasize that mandatory screening represents a necessary baseline for biosecurity, particularly as AI accelerates de novo pathogen design. Critics, however, caution that subjective risk assessments could impose heavy compliance burdens on startups and stifle legitimate research. The coalition behind the letter, spanning ideologically diverse policy think tanks, underscores a rare consensus on the necessity of preventing AI-facilitated biological weaponization. With the potential for engineered pathogens to trigger unprecedented public health crises, the executives stress that proactive regulatory frameworks are essential to align technological advancement with global safety standards.